JP2023526773A5 - - Google Patents
Info
- Publication number
- JP2023526773A5 JP2023526773A5 JP2022564746A JP2022564746A JP2023526773A5 JP 2023526773 A5 JP2023526773 A5 JP 2023526773A5 JP 2022564746 A JP2022564746 A JP 2022564746A JP 2022564746 A JP2022564746 A JP 2022564746A JP 2023526773 A5 JP2023526773 A5 JP 2023526773A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- viral vector
- seq
- functional fragment
- sequence identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025239487A JP2026062601A (ja) | 2020-05-27 | 2025-12-08 | 骨髄性細胞およびミクログリアにおいて特異的に治療タンパク質を発現するウイルスベクター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20176939 | 2020-05-27 | ||
| EP20176939.5 | 2020-05-27 | ||
| PCT/EP2021/059070 WO2021239308A1 (en) | 2020-05-27 | 2021-04-07 | Viral vectors expressing therapeutic proteins specifically in myeloid cells and microglia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025239487A Division JP2026062601A (ja) | 2020-05-27 | 2025-12-08 | 骨髄性細胞およびミクログリアにおいて特異的に治療タンパク質を発現するウイルスベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023526773A JP2023526773A (ja) | 2023-06-23 |
| JP2023526773A5 true JP2023526773A5 (https=) | 2024-04-01 |
| JP7820823B2 JP7820823B2 (ja) | 2026-02-26 |
Family
ID=70918223
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564746A Active JP7820823B2 (ja) | 2020-05-27 | 2021-04-07 | 骨髄性細胞およびミクログリアにおいて特異的に治療タンパク質を発現するウイルスベクター |
| JP2025239487A Pending JP2026062601A (ja) | 2020-05-27 | 2025-12-08 | 骨髄性細胞およびミクログリアにおいて特異的に治療タンパク質を発現するウイルスベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025239487A Pending JP2026062601A (ja) | 2020-05-27 | 2025-12-08 | 骨髄性細胞およびミクログリアにおいて特異的に治療タンパク質を発現するウイルスベクター |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230227847A1 (https=) |
| EP (1) | EP4158035A1 (https=) |
| JP (2) | JP7820823B2 (https=) |
| KR (1) | KR20230018378A (https=) |
| CN (1) | CN115552019A (https=) |
| AU (1) | AU2021280943A1 (https=) |
| BR (1) | BR112022016715A2 (https=) |
| CA (1) | CA3165462A1 (https=) |
| IL (1) | IL298093A (https=) |
| MX (1) | MX2022014766A (https=) |
| WO (1) | WO2021239308A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| US12071633B2 (en) | 2020-10-13 | 2024-08-27 | Kriya Therapeutics, Inc. | Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer |
| US20240033332A1 (en) * | 2020-12-17 | 2024-02-01 | Kyoto University | Agent for activating a neuron |
| WO2023109911A1 (en) * | 2021-12-15 | 2023-06-22 | National Institute Of Biological Sciences, Beijing | Microglia having car and use thereof |
| WO2024036106A1 (en) * | 2022-08-08 | 2024-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | Embryo microglia complementation for in vivo microglia manipulation and production of a non-human animal model for validation of gene function and therapeutic screening |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| US20110223635A1 (en) | 2008-08-11 | 2011-09-15 | Karl Deisseroth | Method and Composition for Controlling Gene Expression |
| WO2016026854A2 (en) | 2014-08-18 | 2016-02-25 | Apceth Gmbh & Co. Kg | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells |
| US20190328906A1 (en) | 2016-03-02 | 2019-10-31 | The Children's Hospital Of Philadelphia | Therapy for frontotemporal dementia |
| US20180186855A1 (en) * | 2016-03-23 | 2018-07-05 | Alector Llc | Chimeric receptors and methods of use thereof |
| WO2018169901A1 (en) * | 2017-03-13 | 2018-09-20 | Massachusetts Institute Of Technology | Synthetic promoters |
| BR112020001060A2 (pt) | 2017-07-27 | 2020-07-14 | Novartis Ag | variantes de trem2 resistentes a shedase |
| CN109868286B (zh) * | 2017-12-05 | 2022-09-16 | 深圳先进技术研究院 | 一种慢病毒载体、慢病毒及其制备方法和应用 |
| JP2021517168A (ja) | 2018-03-09 | 2021-07-15 | アブロバイオ，インコーポレーテッド | パーキンソン病を処置するための組成物及び方法 |
| US20190300870A1 (en) | 2018-04-03 | 2019-10-03 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
| WO2020160458A1 (en) | 2019-02-01 | 2020-08-06 | Avrobio, Inc. | Compositions and methods for treating neurocognitive disorders |
| MX2022003934A (es) * | 2019-10-02 | 2022-04-25 | Univ Zuerich | Tratamiento de la enfermedad granulomatosa cronica. |
-
2021
- 2021-04-07 US US17/998,587 patent/US20230227847A1/en active Pending
- 2021-04-07 BR BR112022016715A patent/BR112022016715A2/pt unknown
- 2021-04-07 MX MX2022014766A patent/MX2022014766A/es unknown
- 2021-04-07 KR KR1020227041496A patent/KR20230018378A/ko active Pending
- 2021-04-07 CA CA3165462A patent/CA3165462A1/en active Pending
- 2021-04-07 IL IL298093A patent/IL298093A/en unknown
- 2021-04-07 CN CN202180034310.3A patent/CN115552019A/zh active Pending
- 2021-04-07 JP JP2022564746A patent/JP7820823B2/ja active Active
- 2021-04-07 AU AU2021280943A patent/AU2021280943A1/en active Pending
- 2021-04-07 WO PCT/EP2021/059070 patent/WO2021239308A1/en not_active Ceased
- 2021-04-07 EP EP21716740.2A patent/EP4158035A1/en active Pending
-
2025
- 2025-12-08 JP JP2025239487A patent/JP2026062601A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526773A5 (https=) | ||
| Zheng et al. | The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy | |
| JP7336457B2 (ja) | 抗体Ｆｃ領域を主鎖として用いた融合タンパク質二量体及びその使用 | |
| JP7460609B2 (ja) | 活性化可能なインターロイキン－２ポリペプチド及びその使用方法 | |
| AU2017213661B2 (en) | Administration of engineered T cells for treatment of cancers in the central nervous system | |
| JP4494977B2 (ja) | Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質 | |
| JP7423607B2 (ja) | インターロイキン ２突然変異タンパク質およびｉ型インターフェロンで構成される融合タンパク質 | |
| TWI850282B (zh) | 用於治療癌症之質體建構體和使用方法 | |
| Cui et al. | CAR‐T therapy: prospects in targeting cancer stem cells | |
| JP2018514199A5 (https=) | ||
| CN108250303B (zh) | 单域抗体融合蛋白及其应用 | |
| BRPI0817108B1 (pt) | composição compreendendo uma proteína de fusão, kit compreendendo a referida composição e uso da mesma. | |
| EP4019536A1 (en) | Immunocytokine, preparation for same, and uses thereof | |
| AU2020243431B2 (en) | A2/NY-ESO-1 specific T cell receptors and uses thereof | |
| JP2021514661A5 (https=) | ||
| US20210155955A1 (en) | Therapeutic constructs for treating cancer | |
| CN115190910A (zh) | 细胞介导的免疫增强分子到肿瘤微环境中的瞬时递送 | |
| CN111615518B (zh) | 阻断emt途径并克服癌干细胞的il8 | |
| KR20240161974A (ko) | 암을 치료하기 위한 il-10을 포함하는 이중 시토카인 융합체 및 입양 세포 요법 또는 이중특이적 t-세포 연관체 | |
| Rybchenko et al. | Targeted cytokine delivery for cancer treatment: engineering and biological effects | |
| WO2023133357A2 (en) | Engineered t cells | |
| JP2006517970A (ja) | 癌免疫療法のための組成物及び方法 | |
| Goutnik et al. | Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme: Literature review and future directions | |
| WO2006046661A1 (ja) | インターロイキン－６阻害剤 | |
| Prodi et al. | Tumor-homing antibody-cytokine fusions for cancer therapy |